Corin

Executive Summary

Corin Group is a UK-based orthopaedic medical device company specializing in hip, knee, ankle, and shoulder implants integrated with proprietary robotic and AI-powered surgical planning platforms. Founded in 1985 and headquartered in Cirencester, the company is private and has not disclosed funding or valuation. Corin's mission is to enhance patient outcomes and accelerate recovery through connected, data-driven orthopaedic technology. The company differentiates itself by combining advanced implants with robotics and AI, positioning it in the competitive orthopaedic robotics market. While Corin has a strong foundation in implant design, its success hinges on adoption of its OMNIBotics® platform and expansion into new geographies. The private status limits financial visibility, but its focus on innovation suggests potential for growth. Key risks include competition from larger players like Stryker and Zimmer Biomet, and regulatory hurdles in key markets. Overall, Corin represents a niche player with potential for disruption if it executes well on its technology roadmap.

Upcoming Catalysts (preview)

• H2 2026FDA or CE Mark approval for next-generation OMNIBotics hip or knee system70% success
• H1 2027Expansion into new geographic markets (e.g., Japan or Australia) via distribution partnerships60% success
• Q4 2026Publication of clinical outcomes demonstrating superiority of AI-assisted surgical planning75% success